What Kalaris Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 2 |
| Sells | 0 | 1 |
| Total trades | 0 | 7 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 2,243,555 |
| Disposed | 0 | 68,821 |
| Net activity | +0 | +2,174,734 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Akkaraju Srinivas | Director | May 20 | Other Transaction · J | +4,471 | — | — | 19,408 |
| Akkaraju Srinivas | Director | May 20 | Other Transaction · J | +14,937 | — | — | 14,937 |
| Akkaraju Srinivas | Director | May 20 | Other Transaction · J | −66,906 | — | — | 10,657,028 |
| Akkaraju Srinivas | Director | May 20 | Open-market buy · P | +244,300 | $4.83 | +$1.18M | 2,224,147 |
| Hagen Brett R | Chief Accounting Officer | Mar 20 | Open-market sale · S | −1,915 | $6.72 | −$12.9K | 0 |
| Akkaraju Srinivas | Director | Dec 22 | Grant / award · A | +1,500,000 | $10.00 | +$15M | 1,500,000 |
| Akkaraju Srinivas | Director | Dec 18 | Open-market buy · P | +479,847 | $10.42 | +$5M | 1,979,847 |
| Hagen Brett R | Chief Accounting Officer | Mar 26 | Open-market sale · S | −907 | $8.97 | −$8.14K | 1,925 |
| Feinsod Matthew | Chief Medical Officer | Mar 18 | Grant / award · A | +4,030 | — | — | 4,030 |
| Patel Samir Chandrakant | Director | Mar 18 | Grant / award · A | +100,800 | — | — | 100,800 |
| Patel Samir Chandrakant | Director | Mar 18 | Grant / award · A | +252,000 | — | — | 252,000 |
| Akkaraju Srinivas | Director | Mar 18 | Grant / award · A | +11,444,503 | — | — | 11,444,503 |
| Ferrara Napoleone | Director | Mar 18 | Grant / award · A | +504,000 | — | — | 504,000 |
| Hagen Brett R | Chief Accounting Officer | Feb 21 | Open-market sale · S | −96 | $10.08 | −$967 | 2,832 |
| Miller Edward | General Counsel | Feb 21 | Open-market sale · S | −106 | $10.08 | −$1.07K | 6,517 |
| Sinha Vikas | See Remarks | Feb 21 | Open-market sale · S | −303 | $10.08 | −$3.05K | 49,129 |
| Hagen Brett R | Chief Accounting Officer | Jan 23 | Open-market sale · S | −4 | $9.94 | −$39.8 | 2,928 |
| Hagen Brett R | Chief Accounting Officer | Jan 23 | Open-market sale · S | −32 | $9.45 | −$303 | 2,932 |
| Miller Edward | General Counsel | Jan 23 | Open-market sale · S | −5 | $9.94 | −$49.7 | 6,623 |
| Miller Edward | General Counsel | Jan 23 | Open-market sale · S | −47 | $9.45 | −$444 | 6,628 |
Loading...